Hyperuricemia in patients with hyperthyroidism due to Graves' disease.
The effects of hyperthyroidism on uric acid metabolism were investigated. First, the serum uric acid level was measured in 92 patients with hyperthyroidism due to Graves' disease, eight patients with subacute thyroiditis, six patients with hypothyroidism, and 70 sex- and age-matched controls. Second, the correlation between serum thyroxine (T4) and serum uric acid was obtained in hyperthyroid Graves' disease patients before and during antithyroid drug therapy. Finally, uric acid clearance (CUA) was determined in untreated patients with hyperthyroidism due to Graves' disease. Serum uric acid was significantly elevated in patients with hyperthyroidism, and the elevation correlated well with serum T4 before treatment as a group and during treatment in each patient. A significant elevation of serum uric acid was not present in patients with a transient mild thyrotoxicosis due to subacute thyroiditis. Serum uric acid was significantly decreased in patients with hypothyroidism. Renal excretion of uric acid clearly increased in hyperthyroid patients, and CUA also increased. The increase in CUA corresponded to the increase in renal plasma flow (RPF), which was measured by p-aminohippuric acid clearance. The fractional excretion of uric acid as determined by CUA/glomerular filtration rate (GFR) was similar and within the normal range in hyperthyroid patients and normal controls. A significant inverse correlation between CUA and serum uric acid concentration was present in hyperthyroid patients as in normal controls, indicating that the renal handling of uric acid in the tubule affected uric acid excretion.(ABSTRACT TRUNCATED AT 250 WORDS)
Sato
A
A
Department of Medicine, Dokkyo Medical College, Koshigaya Hospital, Saitama, Japan.
Shirota
T
T
Shinoda
T
T
Komiya
I
I
Aizawa
T
T
Takemura
Y
Y
Yamada
T
T
D000293:Adolescent; D000328:Adult; D000368:Aged; D002648:Child; D005260:Female; D006111:Graves Disease / Q000150:complications / Q000188:drug therapy / Q000378:metabolism*; D006801:Humans; D006980:Hyperthyroidism / Q000188:drug therapy / Q000209:etiology / Q000378:metabolism*; D007037:Hypothyroidism / Q000378:metabolism; D007668:Kidney / Q000503:physiopathology; D008297:Male; D008713:Methimazole / Q000627:therapeutic use; D008875:Middle Aged; D012039:Regional Blood Flow / Q000187:drug effects; D013974:Thyroxine / Q000097:blood; D014527:Uric Acid / Q000097:blood* / Q000652:urine*
D014527:Uric Acid; D008713:Methimazole; D013974:Thyroxine